A Pharmacokinetic Study of Amphotericin B Lipid Complex Injection (Abelcet) in Patients with Definite or Probable Systemic Fungal Infections-Reference-Cited by-同舟云学术

A Pharmacokinetic Study of Amphotericin B Lipid Complex Injection (Abelcet) in Patients with Definite or Probable Systemic Fungal Infections

Published:2000-10 Issue:10 Volume:44 Page:2900-2902
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Adedoyin Adedayo¹,Swenson Christine E.²,Bolcsak Lois E.²,Hellmann Andrzej³,Radowska Danuta⁴,Horwith Gary²,Janoff Andrew S.²,Branch Robert A.¹

Affiliation:

1. Center for Clinical Pharmacology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania1;

2. The Liposome Company, Inc., Princeton, New Jersey2; and

3. Hematology Department, Medical University of Gdansk,3 and

4. Provincial Hospital of Infectious Diseases,4 Gdansk, Poland

Abstract

ABSTRACT This study describes a pharmacokinetic evaluation of amphotericin B (AMB) lipid complex injection (ABLC or Abelcet) in 17 patients with systemic fungal infection administered 5 mg/kg of body weight/day by infusion for 10 to 17 days. The results showed that AMB exhibited multiexponential disposition with high clearance, large volume of distribution at steady state, and long apparent elimination half-life but no evidence of accumulation in the blood after multiple daily doses. The results confirm previous observations and further reinforce the suggestion that ABLC may exist as a depot in the tissues from which free AMB is slowly released to limit exposure.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.44.10.2900-2902.2000

Reference16 articles.

1. Pharmacokinetic profile of ABELCET (amphotericin B lipid complex injection): combined experience from phase I and phase II studies

2. Development, characterization, efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B.;Adler-Moore J. P.;J. Liposome Res.,1993

3. Behavior of amphotericin B lipid complex in plasma in vitro and in the circulation of rats

4. Amphotericin B: 30 years of clinical experience.;Gallis H. A.;Rev. Infect. Dis.,1990

5. Amphotericin B and its delivery by liposomal and lipid formulations.;Gates C.;J. Clin. Pharm. Ther.,1993

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liposomes as Targeted Drug‐Delivery Systems;Targeted Drug Delivery;2022-11-18

2. Polyene Antibiotics Physical Chemistry and Their Effect on Lipid Membranes; Impacting Biological Processes and Medical Applications;Membranes;2022-06-30

3. Sensitive LC-MS/MS Methods for Amphotericin B Analysis in Cerebrospinal Fluid, Plasma, Plasma Ultrafiltrate, and Urine: Application to Clinical Pharmacokinetics;Frontiers in Chemistry;2021-11-29

4. Antifungals in Clinical Use and the Pipeline;Infectious Disease Clinics of North America;2021-06

5. Complement-mediated hypersensitivity reactions to an amphotericin B-containing lipid complex (Abelcet) in pediatric patients and anesthetized rats: Benefits of slow infusion;Nanomedicine: Nanotechnology, Biology and Medicine;2021-06